Table 1.
The molecular testing panel in tissue/blood samples from 18 patients with EGFR-mutated NSCLC after failing a first-generation kinase inhibitor.
| N# | Driver Alteration | Other Alteration | Kinase Inhibitor | NGS Panel (Tissue) | NGS Panel (Blood) | EGFR T790M ddPCR Stilla® (Blood) |
|---|---|---|---|---|---|---|
| 1 | EGFR exon 21 p. L858R | No | Gefitinib | - | CHP2 *: Not detected | Not detected |
| 2 | EGFR exon 21 p. L858R | No | Gefitinib | - | - | T790M detected |
| 3 | EGFR exon 21 p. L858R | No | Gefitinib | Oncomine® Lung: T790M detected | CHP2 *: Not detected | - |
| 4 | EGFR exon 21 p. L858R | No | Gefitinib | - | CHP2 *: Not detected | Not detected |
| 5 | EGFR exon 19 deletion | TP53 | Gefitinib | MOSC4: T790M not detected | - | - |
| 6 | EGFR exon 19 deletion | No | Gefitinib | - | - | Not detected |
| 7 | EGFR exon 19 deletion | No | Gefitinib | MOSC4: T790M not detected | - | T790M detected |
| 8 | EGFR exon 21 p.L833F | TP53, CKDN2A | Erlotinib | - | - | ddPCR Not detected |
| 9 | EGFR exon 19 deletion | No | Erlotinib | - | - | Not detected |
| 10 | EGFR exon 19 deletion | No | Erlotinib | - | - | Not detected |
| 11 | EGFR exon 19 deletion | No | Erlotinib | - | - | Not detected |
| 12 | EGFR exon 19 deletion | No | Erlotinib | MOSC4: T790M detected | - | T790M detected |
| 13 | EGFR exon 21 p. L858R | No | Erlotinib | Unknown: not detected | - | - |
| 14 | EGFR exon 19 deletion | No | Erlotinib | MOSC4: T790M not detected | - | Not detected |
| 15 | EGFR exon 19 deletion | No | Erlotinib | MOSC4: T790M not detected | - | - |
| 16 | EGFR exon 19 deletion | No | Erlotinib | MOSC4: T790M not detected | CHP2 *: Not detected | - |
| 17 | EGFR exon 21 p. L858R | No | Erlotinib | OCAV3: T790M not detected | Oncomine® Lung: Not detected | - |
| 18 | EGFR exon 19 deletion | No | Erlotinib | NSCLC: T790M not detected | - | Not detected |
(-): Test not performed; ddPCR: droplet digital polymerase chain reaction, CHP2 *: Ion Ampliseq Cancer Hotspot Panel v2 targeting 50 cancer genes (Thermo Fisher Scientific), MOSC4: Gustave Roussy homemade panel targeting 82 genes, OCAV3: Oncomine Comprehensive Assay v3M (Thermo Fisher Scientific) with 161 genes and NSCLC: Sentosa SQ Non-Small Cell Lung Cancer Panel (Vela Diagnostics) targeting 11 genes.